Third Time Is Not A Charm: KEYLYNK-006 Is Latest Keytruda/Lynparza Study To Fail
Executive Summary
Merck said the Phase III study of the combination in non-small cell lung cancer did not meet its dual primary endpoint of overall survival and progression-free survival.